Item 2.02 Results of Operations and Financial Condition.

On January 6, 2023, Ultragenyx Pharmaceutical Inc. (the "Company") issued a press release (the "Press Release") announcing preliminary unaudited fiscal year 2022 total revenue, revenue for Crysvita®,including revenue in the Ultragenyx territories, and revenue for Dojolvi®, cash and investments at 2022 fiscal year end, total 2023 revenue guidance, including revenue guidance for Crysvita® and Dojolvi®, and expected 2023 net cash used in operations. Ultragenyx territories for Crysvita® include the collaboration revenue from the North American profit share territory (U.S. and Canada) and other regions where revenue from product sales are recognized by the Company (Latin America and Turkey) pursuant to the Company's collaboration agreement with Kyowa Kirin, Ltd. The Company expects to report its full year results for the 2022 fiscal year in February 2023. A copy of the Press Release is furnished herewith as Exhibit 99.1.

The information set forth under Item 2.02 and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

Item 7.01 Regulation FD Disclosure.

On January 6, 2023, the Company posted a presentation (the "Presentation") to its website at www.ultragenyx.com in the "Events and Presentations" subsection of the "Investors & Media" tab. The Company is scheduled to present the Presentation at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023.

The information set forth under Item 7.01 and in the Presentation shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01 Financial Statements and Exhibits.



(d)Exhibits
Exhibit No.                              Description
99.1                                       Press Release, dated January 6, 2023.

104                                      The cover page from the Company's
                                         Current Report on Form 8-K dated January
                                         6, 2023 formatted in Inline XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses